Adefovir (GS-0393): Nucleotide Analog Antiviral for HBV Research

Executive Summary:
Adefovir (GS-0393, PMEA) is a chemically defined nucleotide analog antiviral with a molecular weight of 273.19 and a chemical formula of C8H12N5O4P. It specifically inhibits hepatitis B virus (HBV) DNA polymerase, blocking viral replication at submicromolar concentrations (Hadziyannis & Papatheodoridis, 2004). Adefovir is water-soluble at concentrations ≥2.7 mg/mL with ultrasonic treatment and warming, but insoluble in DMSO and ethanol (APExBIO). The compound is primarily for research use, with validated purity (98%) and stable storage at -20°C. Its use is well-documented in HBV research, with established safety and selectivity benchmarks (DOI).

Biological Rationale

Chronic hepatitis B virus (HBV) infection is a global health challenge with significant morbidity and mortality (Hadziyannis & Papatheodoridis, 2004). HBV is a DNA virus that infects hepatocytes and relies on its own DNA polymerase for replication. Conventional therapies, such as interferon-alpha and lamivudine, are limited by tolerability issues and the rapid emergence of viral resistance (DOI). Nucleotide analogs, including Adefovir, address these gaps by targeting the viral DNA polymerase with high selectivity and low resistance rates. Adefovir's chemical properties make it suitable for in vitro and in vivo studies, enabling precise dissection of HBV replication pathways (Adefovir (GS-0393): Optimizing Antiviral Workflows; this article extends the mechanistic context with recent clinical benchmarks).

Mechanism of Action of Adefovir

Adefovir is an acyclic analog of deoxyadenosine-5'-monophosphate (dAMP). It is administered as its prodrug, adefovir dipivoxil, which is rapidly hydrolyzed in plasma or tissues to release active Adefovir (DOI). Intracellular kinases further phosphorylate Adefovir to its diphosphate form, adefovir diphosphate. This metabolite competes with the natural substrate dATP for incorporation by HBV DNA polymerase. Once incorporated, Adefovir diphosphate terminates DNA chain elongation due to its lack of a 3'-hydroxy group, effectively blocking viral replication (DOI).

Evidence & Benchmarks

• Adefovir diphosphate inhibits HBV DNA polymerase with an IC₅₀ of 0.1 μmol/L in vitro, while the IC₅₀ for human DNA polymerase-α is >100 μmol/L (DOI:10.1586/14787210.2.4.475).
• Therapeutic dosing in clinical scenarios (10 mg daily for 48 weeks) is effective for both hepatitis B e antigen-positive and -negative chronic HBV infection (DOI).
• Adefovir demonstrates efficacy against both wild-type and lamivudine-resistant HBV strains (DOI).
• Long-term studies (3+ years) show maintained efficacy with low resistance rates (DOI).
• Adefovir is water-soluble at concentrations ≥2.7 mg/mL with ultrasonic treatment and warming (APExBIO).
• The compound is supplied at ≥98% purity for research use only, with optimal storage at -20°C (APExBIO).

Applications, Limits & Misconceptions

Adefovir is widely used in HBV research as a selective DNA polymerase inhibitor. Its applications include the study of HBV replication, assessment of drug resistance, and evaluation of antiviral strategies in preclinical and translational settings. The compound's selectivity allows for differentiation between viral and host polymerase activities.

For a detailed exploration of Adefovir's pharmacokinetics and transporter interactions, see Adefovir in HBV Research: Beyond Inhibition to Pharmacokinetics—this article updates those workflows with new resistance and solubility benchmarks.

Common Pitfalls or Misconceptions

• Adefovir is not effective against RNA viruses; its mechanism targets DNA polymerase only.
• It is not soluble in DMSO or ethanol; only water with ultrasonic treatment and warming ensures dissolution at ≥2.7 mg/mL (APExBIO).
• The product is not intended for diagnostic or medical use; research use only as specified by APExBIO.
• Long-term storage of Adefovir solutions is not recommended due to potential degradation.
• Clinical dosing/safety cannot be directly extrapolated from research-grade formulations.

For advanced mechanistic safety insights, Adefovir (GS-0393, PMEA): Molecular Mechanisms, Safety Insights offers translational perspectives; this article clarifies product-specific technical and storage parameters.

Workflow Integration & Parameters

Adefovir (APExBIO, SKU: C6629) is supplied as a ≥98% pure solid. For experimental use, dissolve in water at ≥2.7 mg/mL, using ultrasonic treatment and gentle warming to ensure complete solubilization. Avoid DMSO and ethanol as solvents (APExBIO). Store powder at -20°C; avoid long-term storage of solutions due to instability. Shipping is done on Blue Ice for small molecules and Dry Ice for modified nucleotides. Use validated controls and reference standards for DNA polymerase activity assays. For transporter phenotyping, refer to Adefovir (C6629): Molecular Mechanisms and Research Benchmarks, which this article extends with the latest purity and solubility guidance.

Conclusion & Outlook

Adefovir (GS-0393, PMEA) remains a cornerstone nucleotide analog antiviral for HBV research, with a well-validated mechanism as a DNA polymerase inhibitor. Its selectivity, solubility, and stability parameters enable robust experimental design. Continued research is expanding its application in resistance profiling and transporter studies, further refining its role in antiviral discovery pipelines. For ordering and technical documentation, refer to the Adefovir (C6629) product page provided by APExBIO.